Supplementary Table 5.

List of other investigational antiviral therapies against SARS-COV-2 infection

Investigation antiviral agents	Current status	Clinical trial identifier
Ivermectin	Positive in vitro activity against SAR-COV-2 Research is ongoing to evaluate its effectiveness but it’s already being used as both prophylaxis and treatment either alone or in combination with doxycycline	NCT04445311 (phase2/3) NCT04438850 (phase 2) NCT04523831 (phase 3)
Nitazoxanide	Positive in vitro activity against SARS-CoV-2. Being tried as prophylaxis and treatment	NCT04435314 (phase 2) NCT04463264 (phase2/3)
Merimepodib	Novel drug which is an inhibitor of the enzyme inosine monophosphate (IMP) dehydrogenase It is evaluated along with remdesivir.	NCT04410354 (phase 2)
Niclosamide	It is an anthelminthic drug which has shown activity against several viruses. A study has been planned in adults with moderate COVID-19 with gastrointestinal signs and symptoms.	NCT04436458
Umifenovir (arbidol)	It is a fusion inhibitor approved for influenza. Clinical studies of umifenvir alone and in combination with favipiravir has been planned in India.	CTRI/2020/06/025957 CTRI/2020/09/027535
Bemcitinib	Oral small-molecule inhibitor of AXL kinase Preclinical data suggest activity against SARS-CoV-2 infection. It is being evaluated in UK in Phase 2 clinical trial in patients with COVID-19	-
Plitidepsin	Positive in vitro studies. No clinical studies have been registered.	-